AI-powered evaluation using the Model Context Optimization BS Detection Framework, based solely on publicly available website content.
Based on 784 businesses audited.
Medical Devices, Pharma & Biotech BS: ELIQUIS (apixaban) (eliquis.com)
Eliquis presents a regulatory fortress built on a technical swamp. While the safety data is dense and high-substance, the 75% failure rate of its internal clinical navigation makes the site’s claims of being a primary resource for patients feel like hollow marketing.
Immediately resolve the 404 errors on the /vte/, /pediatric/, and /afib/ sub-pages to restore the promised signal. Implement Organization and Drug schema to provide a machine-readable authority footprint. Replace the generic review count widget with links to actual peer-reviewed clinical trial results. Add a specific source citation (e.g., IMS health data) with a date for the ‘#1 Prescribed’ claim to move it from fluff to substance.
The site exhibits high information density in its safety disclosures, with technical passages describing spinal or epidural blood clots and specific medication interactions (NSAIDs, SSRIs). However, the primary H1 ‘THE #1 PRESCRIBED ORAL BLOOD THINNER’ is a bold power claim lacking an immediate numerical citation or data source in the text. Substance is found in the granular dosage descriptions and pediatric weight-based instructions (less than 77 pounds), which provide high technical utility compared to generic marketing fluff.
Blocked resources, unstable DOMs, and redirect heavy paths create blind spots in your semantic graph. Run a full Crawlability & Indexation analysis to map every point where AI loses access to your content.
There is catastrophic semantic drift between the homepage signal and the sub-page delivery. The homepage H3 headings promise dedicated sections for ‘Atrial Fibrillation (AFib)’, ‘Deep Vein Thrombosis (DVT)’, and ‘Pediatric Patients,’ yet the corresponding URLs (/afib/, /vte/, /pediatric/) all return ‘Page Not Found’ errors. This represents a 75% failure rate in the site’s promise to provide specific clinical information for its advertised indications.
Stop the ROI leak caused by technical debt and strategic misalignment. Conduct an Independent Strategic Diagnosis for 1 Euro to identify high impact issues across all audit categories.
The site triggers a major trust theatre flag with a review_count of 7 on the homepage and 6 on 404 pages, yet a proof_links_count of 0. Displaying review metrics without verifiable links to patient testimonials or clinical trial data in a pharmaceutical context is a high-BS signal. The claim of being the ‘#1 prescribed’ medication remains an unsubstantiated performance claim within the provided crawl data.
The proof density is lopsided; legal and safety evidence is overwhelming (citing specific adverse effects like ‘hematoma’ and ‘paralysis’), but clinical proof for efficacy is entirely missing from the crawl due to the failed sub-pages. There are 0 external proof paths to peer-reviewed studies or ClinicalTrials.gov registrations in the provided evidence.
To see how the methodology translates into real diagnostic output, review a full executive level analysis applied to a global fashion retailer. View the Mango Executive SEO Strategy for a concrete example of how structural gaps, semantic weaknesses, and conversion friction are surfaced in practice.
While the core safety text is highly specific to the molecule apixaban, the 404 pages utilize entirely generic template language (‘We are sorry. The page you requested… did not load properly’). The value proposition of support programs like ‘ELIQUIS 360 Support’ follows standard industry cliches but is anchored by specific offers like the ‘Free 30-day trial offer,’ which prevents a maximum commodity penalty.
There is a significant authority gap due to the complete absence of structured data (schema_json is null) and a broken technical hierarchy where 3 out of 4 primary pages fail to resolve. While the site references the FDA and healthcare providers, it lacks Person schema or sameAs links for medical directors or clinical leads, relying entirely on the brand’s weight rather than verifiable expert footprints.
The disconnect between the marketing claim ‘THE #1 PRESCRIBED ORAL BLOOD THINNER’ and the site’s technical state is severe. A market leader should demonstrate technical excellence, yet the site fails to provide the basic infrastructure to support its primary therapeutic claims. The marketing tone is authoritative, but the content delivery is broken.
Medical Devices, Pharma & Biotech BS: ELIQUIS (apixaban) (eliquis.com)
The site strongly matches the Pharma & Biotech category, characterized by extensive mandatory safety disclosures and clinical indications. The presence of Boxed WARNINGS and specific dosage strengths (2.5 mg and 5 mg) confirms its role as a regulated prescription medicine platform.
When links fail to express hierarchy, the model cannot form clusters or identify primary entities. Examine the Internal Linking Technical Guide and understand how structural signals—not navigation—define your semantic map.
“The score is driven primarily by the total collapse of Semantic Coherence and Identity & Authority. While Information Density is high for safety content, the technical failure of the sub-pages (404 errors) and the presence of unverified review counts (Trust Theatre) create a high BS-profile despite the brand's legitimate pharmaceutical status.”
Analysis Disclosure & Source Attribution
Snapshot Date: May 29, 2026
Purpose: This data is presented under “Fair Use” / “Educational Exception” for the purpose of forensic semantic analysis, allowing users to see how machine logic interprets digital signals.
Machine Perception Notice: This evaluation is generated by machine-read logic (MRL). The AI interprets the “Digital Ghost” of a website (code, metadata, and semantic structures), which may differ from what a human sees at the same moment. This is an automated technical diagnostic and not a statement of fact or human opinion regarding the real-world integrity or legitimacy of the business. Any missing or inaccessible elements in the snapshot are treated as machine-read signals, reflecting AI rendering limitations rather than intentional omission.
Notice to the Evaluated Business: This analysis is part of a non-adversarial audit. The results are intended as professional feedback to help improve machine-readability and authority signals. Any company can use these insights for free. When content is updated, a fresh audit can be requested at any time to reflect the current state.
To All Users: You are encouraged to visit the live site at ELIQUIS (apixaban) to view the most current version of their content and see directly what the company offers.